Paolo L. Manfredi, MD

MGGM Therapeutics, Kerhonkson, New York

  • 5Articles
  • 12.5KReads
  • 2023–2025Active
  • 26Collaborators
  • 23Citations

About

Paolo L. Manfredi, MD is affiliated with MGGM Therapeutics, Kerhonkson, New York. Paolo L. Manfredi has authored or co-authored 5 peer-reviewed articles published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders between 2023 and 2025. Their work focuses on Depression (MDD).

Publications

JCP
Esmethadone (REL-1017) in Patients with Major Depressive Disorder and Antidepressant Tachyphylaxis
Original Research

Esmethadone (REL-1017) in Patients with Major Depressive Disorder and Antidepressant Tachyphylaxis

October 6, 2025

Esmethadone may be a potentially safe and effective adjunctive treatment for patients with MDD and antidepressant tachyphylaxis.
, , , et al
JCP
Reasons for Maintaining the Classification of Esmethadone as an Investigational Uncompetitive NMDAR Antagonist Rapid Antidepressant: Reply to Ferré and Michaelides
Letter to the Editor

Reasons for Maintaining the Classification of Esmethadone as an Investigational Uncompetitive NMDAR Antagonist Rapid Antidepressant: Reply to Ferré and Michaelides

September 8, 2025

The authors reply to Ferré and Michaelides’ letter commenting on their recent study of long-term esmethadone treatment in MDD.
, , , et al
JCP
Long-Term Safety and Efficacy of Esmethadone in MDD
Original Research

Long-Term Safety and Efficacy of Esmethadone in MDD

February 17, 2025

A durable improvement in MDD symptoms for up to 1 year was observed with esmethadone with high rates of response and remission.
, , , et al
JCP
Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants
Original Research

Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants

June 17, 2024

Although this trial of esmethadone did not meet its primary outcome, some secondary and post hoc outcomes were promising.
, , , et al
PCC
REL-1017 Effects on Cognition in MDD
Original Research

REL-1017 Effects on Cognition in MDD

February 14, 2023

REL-1017 improved subjective measures of cognitive impairment, in addition to improving total MADRS and SDQ scores.
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe